



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/715	A1	(11) International Publication Number: WO 98/52578 (43) International Publication Date: 26 November 1998 (26.11.98)
(21) International Application Number: PCT/EP98/02864 (22) International Filing Date: 14 May 1998 (14.05.98) (30) Priority Data: 97870069.8 20 May 1997 (20.05.97) EP (34) Countries for which the regional or international application was filed: BE et al. (71) Applicant (for all designated States except US): TIENSE SUIKERRAFFINADERIJ N.V. [BE/BE]; Tervurenlaan 182, B-1150 Brussel (BE). (72) Inventors; and (75) Inventors/Applicants (for US only): VAN LOO, Jan [BE/BE]; Lepelstraat 3, B-3000 Leuven (BE). FRIPPIAT, Anne [BE/BE]; Abelooslaan 14, B-1933 Sterrebeek (BE). (74) Agent: HERMANS, Johnny; Tiense Suikerraffinaderij N.V., Aandorenstraat 1, B-3300 Tienen (BE).		(81) Designated States: AU, CA, CN, ID, JP, KR, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: FRUCTAN CONTAINING COMPOSITION FOR THE PREVENTION AND TREATMENT OF COLON CANCER		
(57) Abstract <p>The use is provided of a fructan with an average degree of polymerisation of at least 15 for the manufacture of a composition for the prevention and/or treatment of colon cancer in non-bovine mammals, particularly in human beings. Also provided is a method of prevention and treatment of colon cancer in a non-bovine mammal, particularly in a human being, comprising administering to said mammal a composition comprising an effective dose of a fructan with an average degree of polymerisation of at least 15. The said composition can be a medicament as well as a functional food. In a preferred embodiment the fructan is inulin, more preferably inulin with an average degree of polymerisation of at least 20.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

FRUCTAN CONTAINING COMPOSITION FOR THE PREVENTION AND TREATMENT OF COLON CANCER

5

Field of the invention.

10 The present invention relates to the use of certain fructans, preferably certain inulins, for the manufacture of a composition for the prevention and/or treatment of colon cancer in non-bovine mammals.

The present invention also relates to the use of compositions comprising certain fructans, preferably certain inulins, for the prevention and/or treatment of colon cancer in non-bovine mammals, and to a method of prevention and/or treatment of colon cancer in non-bovine mammals.

15

Background of the invention.

20 Cancer in mammals is a disease which is already known from Ancient Times. Nowadays cancer, particularly lung, breast and colon cancer, has become one of the major causes of death of non-bovine mammals, in particular of humans, in the industrialised world.

25 The cancer disease is known to proceed in several steps, including genesis of cells of modified genome and functionality resulting in the formation of malignant cells; uncontrolled local proliferation of the malignant cells and invasion of adjacent normal body structures; and metastasis. During metastasis malignant cells are spread in a body cavity and/or throughout the body via the blood stream and/or the lymph; with invasion of various normal body structures. The invasion of the normal body structures results in their malfunctioning and/or destruction, eventually leading to the death of the affected mammal.

30 Various factors which can provoke carcinogenesis and cancer have already been identified, including certain viral infections, exposure to ionising radiation, exposure to certain mineral fibres, exposure to chemical mutagens, and improper diet.

35 As a result thereof various preventive measures have been introduced which have shown to be successful in preventing or reducing the occurrence of certain cancers.

Furthermore, various surgical and chemotherapeutical methods have been developed for the treatment of cancer. According to the type of cancer, the stage of the disease and the particulars of the affected mammal, these methods have been shown effective to a more or lesser degree.

5 Many reliable animal models for the study of the genesis and evolution of various cancers are available at present, enabling the evaluation of the preventive and curative properties of miscellaneous chemicals and dietary products.

10 Epidemiological studies in combination with studies on animal models have lead to the identification of dietary fibres as an important factor in the prevention and inhibition of certain cancers in mammals.

Dietary fibres are commonly defined as components of plant cells which are resistant to hydrolysis by the alimentary enzymes of man. Dietary fibres comprise cellulose, hemicellulose, polysaccharides, pectin, gums, 15 waxes and lignin. According to this definition, fructans, which are soluble and edible polysaccharides, are dietary fibres. Fructans are composed of chains of carbohydrates which consist mostly of fructose units and in which fructosyl-fructose linkages constitute the majority of the linkages. Fructans commonly occur as polydisperse carbohydrates. They occur in plants, but 20 they also can originate from bacterial activity and they can be synthesised enzymatically as well. All these fructans present typical dietary fibre properties; they are embraced by the present invention and are referred to herein as fructan(s).

Fructans are well known compounds including levan and inulin 25 carbohydrates. Levans are D-fructans generally consisting of chains of fructose units which are essentially connected to each other by $\beta(2-6)$ linkages. Inulins are also D-fructans generally consisting of chains of fructose units but which are essentially connected to each other by $\beta(2-1)$ linkages. Most of the inulin chains terminate in one glucose unit.

30 Levans may occur as linear chain carbohydrates but they are mostly composed of branched fructose chains, whereas inulins are generally composed of linear chain carbohydrates but they may also occur as chains of fructose units which are branched to a larger or lesser extent. Levans and inulins which are suitable according to the present invention include linear 35 and branched chain carbohydrates, as well as mixtures of said linear and branched chain carbohydrates.

Inulins occur in many plants and crops and can occur at concentrations of about 10 to 20 % on fresh weight in chicory, dahlia tubers and Jerusalem artichoke. They can be isolated from these plants, purified, and optionally refined to remove impurities and undesired fractions of carbohydrates, at industrial scale, according to well known techniques.

Inulins can be represented by the general formulae GF_n and F_m wherein G represents a glucose unit, F represents a fructose unit, n represents the number of fructose units linked to the terminal glucose unit, and m represents the number of fructose units linked to each other in the carbohydrate chain.

The number of saccharide units (fructose and glucose units) in one fructan molecule, i.e. the values $n+1$ and m in the above formulae, are commonly referred to as the degree of polymerisation and represented as (DP). Often the parameter average degree of polymerisation (\overline{DP}) is used too, which is the value corresponding to the total number of saccharide units divided by the total number of saccharide molecules present in a given (poly)saccharide composition.

Inulin from plant origin is a polydisperse composition of fructose chains with a degree of polymerisation (DP) ranging from 2 to about 100, whereas inulin from bacterial origin usually has a higher degree of polymerisation.

Fructans, including inulins of general formulae GF_n and F_m , with a lower degree of polymerisation, usually defined as a $(DP) < 10$, are commonly named oligofructoses and are referred to herein accordingly.

Inulin is commercially available. For example, inulin from chicory is available as RAFTILINE® from ORAFTI, (Tienen, Belgium), in various grades. Typical RAFTILINE® grades are, for example, ST, ST-Gel and GR (which have an average degree of polymerisation (\overline{DP}) of 10 and contain in total about 8 % by weight glucose, fructose and sucrose), LS (which has also an average degree of polymerisation of 10 but which contains in total less than 1 % by weight glucose, fructose and sucrose), and HP (high performance inulin) and HP-Gel (which have an average degree of polymerisation of ≥ 23 , commonly about 25, and are essentially free of glucose, fructose and sucrose).

Oligofructoses are usually obtained by partial, acidic or enzymatic hydrolysis of inulins and can also be obtained by enzymatic synthesis from sucrose, according to techniques which are well-known in the art.

Oligofructoses are commercially available. Several grades of oligofructose are, for example, available from ORAFTI, (Tienen, Belgium), as RAFTILOSE®, e.g. RAFTILOSE® P95 which contains about 95 % by weight oligofructoses with a degree of polymerisation ranging from 2 to 7 and about 5 % by weight in total of glucose, fructose and sucrose.

State of the art.

Dietary fibres, in particular fructans, are known to have effects on various physiological functions and mechanisms in mammals.

In non-bovine mammals, these fibres are almost not metabolised in the mouth, the stomach and the small intestine, and they thus almost quantitatively enter the large intestine where they are completely fermented by the colonic microflora. This phenomenon results in various beneficial health effects in non-bovine mammals such as, for example, a reduction of the intestinal transit time, a decrease of the intestinal pH, a bifidus stimulating activity in the colon, an increase of the stool weight (bulking) and stool frequency.

Fructans, particularly inulin, are also known to have a beneficial effect on lipid metabolism, including a lowering effect on blood cholesterol and on serum triglycerides, and an increasing effect on the HDL/LDL ratio.

P.D. Cooper et al., *Molecul. Immunol.*, **23** (8), 895, (1986), describe the activation of the alternative pathway of complement by gamma-inulin (a specific polymorphic form of dahlia inulin), and it is known that an activator of the alternative pathway of complement can have a potential non-specific anti-tumour effect.

Furthermore, fructans, particularly inulin, are described to have potential in the prevention and inhibition of cancer.

P.D. Cooper et al., (*Molecul. Immunol.*, **23** (8), 903, (1986) have demonstrated that intraperitoneally injected gamma-inulin can prolong the survival of melanoma bearing mice.

It has also been disclosed that cultures of bifidobacteria inhibit 2-amino-3-methyl-imidazol[4,5-f]quinoline induced colon, liver, and mammary carcinogenesis (B.S. Reddy et al., *Cancer Res.*, **53**, 3914-3918, (1993) and azoxymethane-induced colon carcinogenesis (N. Kulkarni et al., *Proc. Soc. Exptl. Biol. Med.*, **207**, 278-283, (1994) in rats.

European patent application EP 0 692 252 A1 discloses the suppressing effect of the oligofructose RAFTILOSE® P95 (ex ORAFTI,

Belgium; consisting of 95 % of oligofructose chains with a degree of polymerisation (DP) between 2 and 7) and of the inulins RAFTILINE® ST, GR and LS, (defined hereinbefore and having an average degree of polymerisation of about 10) on breast carcinogenesis induced by injection of N-methylnitrosourea (MNU) in rats as well as on the growth of the transplantable TLT tumour (Taper Liver Tumour) in mice. The investigated oligofructose and inulins showed to have about equal carcinogenesis protective and cancer inhibiting effects.

Furthermore, the relation between the intake of dietary fibres and the reduction of the risk of colon cancer has been disclosed in several publications, e.g. J. Potter et al., Principles of Chemoprevention, IARC Scientific Publication N° 139, 61-90, (1996); G.R. Howe et al., J. Natl. Cancer Inst., 84, 1887-1896, (1992); and B.S. Reddy et al., Gastroenterol., 102, 1475-1482, (1992).

However, in spite of the enormous efforts already made in the fight against cancer diseases, and colon cancer in particular, the prevention and successful inhibition and curing of colon cancer is not always possible yet. Therefore, Medicine is still looking for improving the prevention, inhibition and curing of colon cancer. For various reasons such as the patient's comfort, chemotherapeutical methods are most preferred. Accordingly, there is a continuously ongoing search for improved and/or alternative compositions and therapeutical methods presenting a beneficial effect with respect to the inhibition and/or treatment of colon cancer, and /or presenting less undesirable side effects compared to known compositions and therapeutical methods.

Description of the invention.

The applicant is providing by the present invention a solution to one or more of the above mentioned problems, which even may present additional advantages.

By the term colon cancer is meant herein the colon cancer disease in any of its steps, including colon carcinogenesis, the formation of malignant cells in the colon, proliferation of said malignant cells and formation of tumours in the colon and /or invasion of normal colon structures by said malignant cells.

The invention is based on the findings made by the inventors during extensive studies that fructans with a higher degree of

polymerisation, in particular fructans having an average degree of polymerisation of 15 or higher, present improved preventive and inhibiting properties against colon cancer in non-bovine mammals compared to fructans with a lower degree of polymerisation.

5 In view of the prior art, it could be expected that fructans with a higher degree of polymerisation, could, as do certain fructans with a lower degree of polymerisation, have preventive and/or inhibitive properties against colon cancer. However, the surprising findings of the inventors that fructans, in particular inulins, with a higher average degree of
10 polymerisation, present significantly enhanced preventive and inhibiting properties against colon cancer in non-bovine mammals, compared to fructans with a lower average degree of polymerisation, could not be expected at all having regard to the state of the art.

Accordingly, in one aspect, the present invention relates to the use
15 of a fructan with an average degree of polymerisation of at least 15 for the manufacture of a composition for the prevention and/or treatment of colon cancer in non-bovine mammals, particularly in human beings.

In another aspect, the invention relates to the use of a composition comprising a fructan with an average degree of polymerisation of at least 15,
20 for the prevention and/or treatment of colon cancer in non-bovine mammals, particularly human beings.

In a further aspect, the invention relates to a method for the prevention and/or treatment of colon cancer in non-bovine mammals, particularly human beings, by administering to said mammal susceptible of
25 colon cancer, in need of such prevention or treatment, a composition comprising an effective dose of a fructan with an average degree of polymerisation of at least 15.

In one preferred embodiment, the fructan is levan, preferably with an average degree of polymerisation of at least 20, more preferably ranging
30 from 20 to 50.

In another preferred embodiment, the fructan is inulin, preferably with an average degree of polymerisation of at least 20, even more preferably ranging from 20 to 70. In a further preferred embodiment, the inulin has an average degree of polymerisation ranging from 20 to 40. A typically
35 preferred inulin has an average degree of polymerisation about 25.

Inulin essentially consisting of linear polysaccharide chains or inulin containing up to about 2 % by weight branched polysaccharide chains,

are suitable according to the invention, but inulin containing a higher percentage of branched chains and even inulin essentially consisting of branched polysaccharide chains, and even mixtures of said linear and branched inulins, are suitable as well according to the invention. Typical
5 inulins suitable according to the present invention are chicory inulins, for example RAFTILINE® HP and RAFTILINE® HP-Gel (both high performance inulins [in short HP inulin] ex ORAFTI, Belgium), with an average degree of polymerisation of about 25.

By the term composition according to the present invention is
10 meant herein a medicament, (i.e. a composition which has a prophylactic and/or a curative effect on a mammal to which it has been administered), as well as a functional food, (i.e. a food product for human beings or for a non-human mammal, containing an additional functional ingredient, and which
15 apart from its nutritional properties, additionally provides to that being one or more beneficial physiological effects). In the functional food compositions according to the present invention, said additional functional ingredient is meant to be a fructan, including levans and inulins, as defined herein before. Typical beneficial physiological effects are, for example, beneficial effects on
20 the digestive tract, effects on lipid metabolism and preventive effects against cancer, in particular colon cancer.

When, in accordance with the present invention, the composition is a medicament, it can consist of the defined fructan or it can comprise said fructan in combination with any pharmaceutically acceptable carrier, and optionally also in combination with one or more physiologically active
25 compounds, drugs or prodrugs. Said medicament can have any form known in the art, and can be administered according to known methods. Preferably, the medicament is in the form of a powder, a tablet, a soft gel capsule, a syrup, a solution or a suspension, and is administered orally. However, when present in an appropriate galenic form, the composition can also be
30 administered parenterally, via tube feeding or rectally.

When the composition according to the present invention is a functional food, it is orally administered and it can be present in any known food form, such as, for example, a table spread, a dairy product such as e.g. a milk, a dairy dessert, a yoghurt, or a cheese, an alcoholic or non-alcoholic
35 drink, a bakery product, a chocolate, an ice cream, a meat product, a fruit preparation, a confectionery product, a cereal product, a sauce, a soup, a snack, a dry mix, a meal replacer, a pet food, and the like.

The daily dosis effective in providing prevention against colon cancer preferably ranges, depending from the mammal species and the fructan species, from 0.01 to 2 g/kg body weight, more preferably from 0.05 to 0.5 g/kg body weight.

5 The daily dosis effective in providing an inhibitive and/or curing effect on colon cancer preferably ranges, depending from the mammal species, the fructan species and the stage of development of the colon cancer, from 0.2 to 3 g/kg body weight, more preferably from 0.5 to 1.5 g/kg body weight.

10 In the method of prevention and/or treatment, including inhibition and/or curing, of colon cancer in non-bovine mammals, preferably human beings, the daily dose of the composition according to the present invention described hereinbefore, can be administered to a said mammal susceptible of colon cancer and in need for such treatment, according to
15 known methods in one or more unit doses during a shorter or longer period of time, in function of strength of the effect provided by the composition. When the composition is a functional food and a preventive effect is aimed at, the functional food is advantageously administered in one or more forms over a longer period of time, most preferably during the whole lifetime of the
20 mammal.

 Besides the improved physiological, prophylactic and/or therapeutical effects of the fructans with a higher degree of polymerisation compared to fructans with a lower degree of polymerisation, the compositions and method of treatment according to the present invention
25 present significantly additional advantages. The compositions, for example, are easy to take in or to administer, and the method of treatment is easy to apply, without significant discomfort for the concerned mammal. Furthermore, the presence of fructan chains with a higher degree of polymerisation reduces certain discomforts often encountered with the
30 intake of non-digestible carbohydrates such as e.g. soft stools, diarrhea, flatulence, bloating and intestinal cramps.

 A further considerable advantage presented by the fructans, in particular the preferred chicory inulin, relating to the present invention, is that they are naturally occurring, biodegradable products which are deprived of toxic
35 effects and that they can be taken in and administered to newborn as well as adult, including pregnant, and aged mammals. Compared to many known chemo-therapeutical compositions, the intake of, administration of, and the

treatment with a composition comprising the above defined fructans according to the present invention, is usually very well supported by the mammal and does not provoke significant undesirable side effects or a significant discomfort, if any at all, to the mammal. Furthermore, the fructans suitable according to the present invention are largely commercially available at acceptable cost.

Experimental part.

In support of the present invention, the following illustrative experimental data are given regarding a study made to determine the effect of oligofructose and HP inulin on carcinogen-induced colonic aberrant crypt foci (ACF) formation in rat.

Aberrant crypt foci (ACF), which are recognized as early preneoplastic lesions in the colon, have consistently been observed in experimentally induced colon carcinogenesis in laboratory animals (McLellan, E.A. et al., *Cancer Res.*, **51**, 5270-5274, (1991). and Wargovich, M.H., et al., *Cancer Epidemiol Biomarkers & Prev.*, **5**, 355-360, (1996)). Pretlow, T.P., et al., *J. Cell. Biochem.*, **16G** (Suppl.), 55-62, (1992), have also shown that these lesions are present in the colonic mucosa of patients with colon cancer and have suggested that aberrant crypts are putative precursor lesions from which adenomas and carcinomas may develop in the colon. ACF express mutations in the *apc* gene and *ras* oncogene that appear to be biomarkers of colon cancer development (Vivona, A.A., et al., *Carcinogenesis* (Lond.) **14**, 1777-1781, (1993)).

There is some evidence that several inhibitors of ACF formation reduce the incidence of colon tumors in laboratory animals (Wargovich, M.H., et al., *Cancer Epidemiol Biomarkers & Prev.*, **5**, 355-360, (1996)), suggesting that ACF induction can be used to evaluate novel agents for their potential chemopreventive properties against colon cancer.

30

MATERIALS AND METHODS

Animals, diets, carcinogen, and chemopreventive agents.

5 Azoxymethane (AOM) was obtained from Ash Stevens (Detroit, MI, USA). RAFTILOSE® P95 and RAFTILINE® HP which contained on dry
matter mainly oligofructose (95%) and inulin (99.5%), respectively, were
obtained from ORAFTI (Tienen, Belgium). RAFTILOSE® which was
produced by partial enzymatic hydrolysis of chicory inulin is a polydisperse
β [2-1] fructan with a (DP) ranging between 2 and 7 and a (\overline{DP}) of 4.5.
10 RAFTILINE® HP (i.e. high performance inulin and abbreviated herein to HP
inulin) is chicory inulin of which the lower (DP) fraction has been removed.
Its (DP) ranges between 10 and 60 and it has a (\overline{DP}) of 25. This choice of test
substrates thus allows to observe effects of the degree of polymerisation.

Weanling male F344 rats were obtained from Charles River
15 Breeding Laboratories (Kingston, NY, USA). All ingredients of the AIN-76A
semipurified diet were obtained from Dyets Inc., (Bethlehem, PA, USA) and
were stored at 4°C until the experimental diets were prepared. The
percentage composition of semipurified diet is as follows : casein, 20; D,L-
methionine, 0.3; corn starch, 52; dextrose, 13; corn oil, 5; alphacel, 5; mineral
20 mix (AIN-76A), 3.5; vitamin mix (AIN-76A), 1; and choline bitartrate, 0.2
(Reddy B.S., et al., *Cancer Res.*, 48, 6642-6647, (1988). The rats were held in
quarantine for 1 week and had access to modified AIN-76A semipurified
control diet. They were randomly distributed by weight into various dietary
groups and were transferred to an animal holding room where they were
25 housed in plastic cages, three rats/cage, under controlled conditions of a 12 h
light/ 12 h dark cycle, 50% relative humidity, and 21°C room temperature.
RAFTILOSE® and RAFTILINE® were added to the control diet at 10% level
at the expense of starch.

Experimental procedure. Beginning at 5 weeks of age, groups of
30 animals were fed the control or experimental diets. All animals except the
vehicle-treated rats received AOM s.c. once weekly at 7 and 8 weeks of age at
a dose rate of 15 mg/kg body weight/week. Animals intended for vehicle
treatment were given an equal volume of normal saline. The rats were
continued on control or experimental diets until the termination of the study,
35 when they were 16 weeks of age. All animals were sacrificed by CO₂
euthanasia. The colons were removed, flushed with Krebs-Ringer solution,
opened from cecum to anus, and fixed flat between two pieces of filter paper

in 10% buffered formalin. After a minimum of 24 h in buffered formalin, the colons were cut into 2-cm segments, placed in a Petri dish containing 0.2% methylene blue in Krebs-Ringer solution and kept for 5-10 min. They were then placed, mucosal side up, on a microscope slide and observed through a light microscope. ACF were recorded according to standard procedures (McLellan E.A., et al., *Cancer Res.*, 51, 5270-5274, (1991)).

Aberrant crypts were distinguished from the surrounding normal crypts by their increased size, significantly increased distance from lamina to basal surface of cells, and the easily discernible pericryptal zone. Crypt multiplicity was determined as the number of crypts in each focus and categorised as those containing up to three, or four or more aberrant crypts/focus. All colons were scored by one observer without knowing the identity of agents under study; scores were checked at random by a second observer.

Statistical Analysis. All results were expressed as the means \pm SD and were analysed by one-tailed Student's *t*-test. Differences were considered statistically significant at $p < 0.05$.

RESULTS

General Observations. The body weights of AOM-and vehicle-treated animals fed the control and experimental diets containing 10% inulin or oligofructose were comparable throughout the study (Table 1, hereafter). There were no signs of any adverse effects in liver, kidney, stomach, intestine or lungs of animals fed inulin or oligofructose.

Aberrant Crypt Foci. Table 2 hereafter summarises the AOM-induced ACF in the colon of rats fed the control and experimental diets. The animals administered saline (vehicle) and fed the control and experimental diets containing inulin or oligofructose showed no evidence of ACF formation in the colon (data not shown). In the animals fed the control diet, AOM treatment induced on the average about 120 ACF/colon. ACF were predominantly observed in the distal colons. Efficacy end points used in this study were inhibition of the total number of ACF/colon as well as the reduction of the number of multicrypt clusters (2 or more) of aberrant crypts/focus. Administration of oligofructose or HP inulin in the diet significantly suppressed the total number of ACF/colon as compared to the control diet; the degree of inhibition was significantly more pronounced in the animals fed HP inulin ($p < 0.006$) than in those fed oligofructose ($p < 0.02$).

Crypt multiplicity in terms of 2 or 3 aberrant crypts/focus was also significantly inhibited in animals fed HP inulin ($p < 0.02 - 0.0001$) or oligofructose ($p < 0.04 - 0.01$).

5 Because multiplicity of aberrant crypts has been a probable predictor of colon tumor outcome (Pretlow, T.P., et al., *Carcinogenesis* (Lond.), 13, 1509-1512, (1992)), the present study used this criterion to evaluate oligofructose and HP inulin for their potential inhibitory properties.

10 The results of the present study indicate that orally taken oligofructose and HP inulin inhibits AOM-induced colonic ACF formation in rats supporting the potential colon tumor inhibitory properties of chicory fructans. The experimental results clearly demonstrate that the preventive and ACF inhibitory properties provided by a fructan (*in casu* HP inulin) with a higher average degree of polymerisation, are considerably enhanced compared to a
15 fructan (oligofructose) with a lower average degree of polymerisation.

Table 1. Body weights of animals fed the control diet and experimental diets containing oligofructose and HP inulin.

Experimental groups	Body weights (grams) on control and experimental diets at week			
	0	3	6	10
AOM-treated				
1. Control diet	119 ± 5.9 ^a	173 ± 9.1	257 ± 11	320 ± 14
2. Oligofructose, 10%	119 ± 6.6	167 ± 9.8	258 ± 15	327 ± 16
3. HP Inulin, 10%	120 ± 7.1	73 ± 7.8	259 ± 12	328 ± 15
Saline-treated				
4. Control diet	117 ± 8.5	179 ± 9.7	256 ± 9.8	329 ± 12
5. Oligofructose, 10%	120 ± 5.9	175 ± 7.3	264 ± 9.3	338 ± 12
6. HP Inulin, 10%	119 ± 5.7	171 ± 6.0	256 ± 8.1	329 ± 13

^a Mean ± SD

Table 2. Effect of dietary oligofructose and HP inulin on colonic ACF formation in male F344 rats.

Experimental groups	Total ACF/colon	Foci containing number of aberrant crypts			
		1 crypt/focus	2 crypts/focus	3 crypts/focus	4 or more crypts/focus
Control diet	120 ± 28	19.5 ± 7.3	43.7 ± 7.8	28.2 ± 7.5	28.3 ± 8.2
Oligofructose, 10%	92 ± 28 ^b (p<0.024)	15.4 ± 7.5	31.2 ± 13 ^b (p<0.01)	21.3 ± 7.8 ^b (p<0.04)	23.9 ± 8.2
HP Inulin, 10%	78 ± 37 ^b (p<0.006)	15.7 ± 8.2	24 ± 12 ^b (p<0.0001)	16.6 ± 7.2 ^b (p<0.02)	21.8 ± 14.2

^a Mean ± SD^b Significantly different from the control diet. The level of significance is shown in parenthesis.

CLAIMS

1. Use of a fructan with an average degree of polymerisation of at least 15 for the manufacture of a composition for the prevention and/or treatment of colon cancer in non-bovine mammals.
2. Use according to claim 1 wherein the mammal is selected from the group consisting of a human being, a dog and a cat.
3. Use according to any of claims 1 or 2 wherein the fructan is a levan.
4. Use according to claim 3 wherein the levan has an average degree of polymerisation of at least 20.
5. Use according to any of claims 1 or 2 wherein the fructan is an inulin.
6. Use according to claim 5 wherein the inulin has an average degree of polymerisation of at least 20.
7. Use according to claim 6 wherein the inulin is chicory inulin with an average degree of polymerisation of about 25 and which is essentially free of glucose, fructose and sucrose.
8. Use according to any of claims 1 to 7 wherein the composition is a medicament.
9. Use according to claim 8 wherein the medicament comprises said fructan in combination with a pharmaceutically acceptable carrier and optionally with a physiologically active compound, a drug or a pro drug.
10. Use according to any of claims 1 to 7 wherein the composition is a functional food.
11. Use of a composition as defined in any of claims 1 to 10 for the prevention and/or treatment of colon cancer in a non-bovine mammal.
12. Method of prevention of colon cancer in a non-bovine mammal comprising administering to said mammal susceptible of colon cancer in need of such treatment, a composition comprising an effective dose of a fructan with an average degree of polymerisation of at least 15.
13. Method according to claim 12 wherein the daily dose of fructan administered in one or more unit doses, ranges from 0.01 to 2 g/kg body weight.
14. Method of treatment of colon cancer in a non-bovine mammal comprising administering to said mammal in need of such treatment, a

composition comprising an effective dose of a fructan with an average degree of polymerisation of at least 15.

5 15. Method according to claim 14 wherein the daily dose of fructan administered in one or more unit doses, ranges from 0.2 to 3 g/kg body weight.

16. Method according to any of claims 12, 13, 14 or 15 wherein the mammal is selected from the group consisting of a human being, a dog and a cat.

10 17. Method according to claim 16, wherein the fructan is a levan.

18. Method according to claim 16 wherein the fructan is an inulin.

19. Method according to claim 18 wherein the inulin has an average degree of polymerisation of at least 20.

15 20. Method according to claim 19 wherein the inulin is chicory inulin with an average degree of polymerisation of about 25 and which is essentially free of glucose, fructose and sucrose.

21. Method according to any of claims 12 to 20 wherein the composition is a functional food.

20 22. Method according to any of claims 12 to 20 wherein the composition is a medicament.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/02864

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/715

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	HAMBLY ET AL.: "Effects of high and low risk diets on biomarkers of colon cancer in human-flora-associated (HFA) rats" ANTICANCER RESEARCH, vol. 15, no. 5a, 1995, pages 1656-1657, XP002046243 see abstract no 83	1-22
Y	EP 0 692 252 A (RAFFINERIE TIRLEMONTTOISE SA) 17 January 1996 cited in the application see in particular claims 1-12, examples 3,4,7 -/-	1-22



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

9 September 1998

Date of mailing of the international search report

06/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Isert, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/02864

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PATENT ABSTRACTS OF JAPAN vol. 014, no. 439 (C-0761), 19 September 1990 & JP 02 172921 A (NITTO DENKO CORP), 4 July 1990, see abstract	1-22
A	PATENT ABSTRACTS OF JAPAN vol. 009, no. 228 (C-303), 13 September 1985 & JP 60 089427 A (DAINIPPON SEIYAKU KK), 20 May 1985, see abstract	1-22
A	PATENT ABSTRACTS OF JAPAN vol. 012, no. 333 (C-526), 8 September 1988 & JP 63 093729 A (SEKISUI CHEM CO LTD), 25 April 1988, see abstract	
A	GIBSON ET AL.: "Selective stimulation of bifidobacteria in the human colon by oligofructose and inulin" GASTROENTEROLOGY, vol. 108, no. 4, 1995, pages 975-82, XP002046244 see the abstract, and penultimate paragraph at page 981	1-22
P,X	REDDY ET AL.: "Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition" CARCINOGENESIS, vol. 18, no. 7, July 1997, pages 1371-1374, XP002046245 see the whole document	1-22
P,X	ROWLAND ET AL.: "Effect of Bifidobacterium longum and inulin on gut bacterial metabolism and carcinogen-induced aberrant crypt foci in rats" CARCINOGENESIS, vol. 19, no. 2, February 1998, pages 281-285, XP002076980 *see in particular the abstract*	1-22

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/02864

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0692252 A	17-01-1996	US 5721345 A	24-02-1998